|
|
| (105 intermediate revisions by 15 users not shown) |
| Line 1: |
Line 1: |
| {{Pneumonia}}
| | __NOTOC__ |
| {{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.D.]] [mailto:psingh@perfuse.org]; [[Philip Marcus, M.D., M.P.H.]][mailto:pmarcus192@aol.com] | | {| class="infobox" style="float:right;" |
| | |- |
| | |[[File:Siren.gif|30px|link=Community acquired pneumonia resident survival guide]]||<br>||<br> |
| | |[[Community acquired pneumonia resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] |
| | |} |
| | {{Community-acquired pneumonia|classification=Classification}} |
|
| |
|
| ==[[Pneumonia overview|Overview]]==
| | '''For the main page on pneumonia, click [[pneumonia|here]].''' |
|
| |
|
| ==[[Pneumonia pathophysiology|Pathophysiology]]==
| | '''For hospital-acquired pneumonia, click [[hospital-acquired pneumonia|here]].''' |
|
| |
|
| ==[[Pneumonia epidemiology and demographics|Epidemiology & Demographics]]==
| | '''For patient information on pneumonia, click [[Pneumonia (patient information)|here]].''' |
|
| |
|
| ==[[Pneumonia risk factors|Risk Factors]]==
| | {{CMG}}; {{AE}} {{AL}}; {{NH}} |
| | '''Assistant Editor-In-Chief:''' Simran Singh |
|
| |
|
| ==[[Pneumonia natural history, complications, and prognosis|Natural History, Complications & Prognosis]]==
| | {{SK}} CAP |
|
| |
|
| ==[[Pneumonia causes|Causes of Pneumonia]]== | | ==[[Community-acquired pneumonia overview|Overview]]== |
|
| |
|
| ==[[Pneumonia differential diagnosis|Differentiating Pneumonia from other Diseases]]== | | ==[[Community-acquired pneumonia historical perspective|Historical Perspective]]== |
|
| |
|
| ==[[Pneumonia physical examination|Physical Examination]]== | | ==[[Community-acquired pneumonia classification|Classification]]== |
|
| |
|
| ==Diagnosis== | | ==[[Community-acquired pneumonia pathophysiology|Pathophysiology]]== |
| ===Diagnostic criteria for community acquired pneumonia===
| |
| * Patient who has not been hospitalized or in an institutional setting for the past 2 weeks and have the following findings:
| |
| ** CXR findings of a new infiltrate. Although there is no gold standard for the diagnosis of community acquired pneumonia (CAP), a new infiltrate on chest radiograph in the setting of acute respiratory complaints (e.g., cough and dyspnea) is considered highly suggestive of CAP.
| |
| ** Atleast 2 of the four: fever, cough, dyspnea, chest pain
| |
| [[Image:Pneumonia.gif|thumb|right|200px|'''Pneumonia.''' Chest x-ray showing increased shadowing in right lung (Right side of image). <small>(''Source: Center for Disease Control and Prevention''.)</small>]]
| |
|
| |
|
| == Treatment == | | ==[[Community-acquired pneumonia causes|Causes]]== |
| * CAP is treated by administering an antibiotic which is effective in killing the offending microorganism as well as managing any complications of the infection.
| |
| * If the causative microorganism is identified, different antibiotics are tested in the laboratory in order to identify which medication will be most effective.
| |
| * Often, however, no microorganism is ever identified.
| |
| * Also, since laboratory testing can take several days, there is some delay until an organism is identified.
| |
| * In both cases, a person's risk factors for different organisms must be remembered when choosing the initial antibiotics (called [[empiricism|empiric]] therapy).
| |
| * Additional consideration must be given to the setting in which the individual will be treated.
| |
| * Most people will be fully treated after taking oral pills while other people need to be hospitalized for [[intravenous]] antibiotics and, possibly, [[intensive care medicine|intensive care]].
| |
| * In general, all therapies in older children and adults will include treatment for atypical bacteria. Typically this is a macrolide antibiotic such as [[azithromycin]] or [[clarithromycin]] although a [[fluoroquinolone]] such as [[levofloxacin]] can substitute.
| |
| * The treatment of pneumonia involves three critical decisions: firstly whether the patient truly has pneumonia, secondly what is the severity of the pneumonia, and lastly whether hospitalization is required for adequate management.
| |
| === The decision to hospitalize ===
| |
| * Some people with CAP require hospitalization and more intensive care than the majority. [[Clinical prediction rule]]s, such as the [[pneumonia severity index]] and [[CURB-65]] have been developed to help guide the decision{{ref|Fine}}. Factors which increase the need for hospitalization include:
| |
| ** Age > 65 yrs, in most cases, men over 70 and women over 80 should be managed as inpatients when diagnosed with CAP
| |
| ** Confusion
| |
| ** Underlying chronic illnesses;
| |
| ** Evidence of infection outside the lung.
| |
| ** Vitals:
| |
| *** [[Respiratory rate]] > 30 breaths/minute;
| |
| *** [[SBP]] < 90 mmHg;
| |
| *** [[Heart rate]] > 125/min;
| |
| *** [[Temperature]] < 35 or >40°C;
| |
| ** Laboratory results which increase the need for hospitalization include:
| |
| *** Arterial oxygen tension < 60 mm Hg,
| |
| *** [[Carbon dioxide]] > 50 mmHg,
| |
| *** [[pH]] < 7.35 on room air;
| |
| *** [[Hematocrit]] < 30%;
| |
| *** [[Creatinine]] > 1.2 mg/dl or
| |
| *** [[Blood urea nitrogen]] > 20 mg/ dl;
| |
| *** White blood cell count < 4 × 10^9/L or > 30 × 10^9/L; and
| |
| *** Absolute neutrophil count < 1 x 10^9/L.
| |
| *** X-ray findings which increase the need for hospitalization include involvement of more than one lobe of the [[lung]], presence of a cavity, and the presence of a [[pleural effusion]].
| |
|
| |
|
| ===Newborn infants=== | | ==[[Community-acquired pneumonia differential diagnosis|Differentiating Community-acquired pneumonia from other Diseases]]== |
| Most newborn infants with CAP are hospitalized and given [[intravenous]] [[ampicillin]] and [[gentamicin]] for at least ten days. This treats the common bacteria ''[[Streptococcus agalactiae]]'', ''[[Listeria monocytogenes]]'', and ''[[Escherichia coli]]''. If [[herpes simplex virus]] is the cause, intravenous [[acyclovir]] is administered for 21 days.
| |
|
| |
|
| ===Children=== | | ==[[Community-acquired pneumonia epidemiology and demographics|Epidemiology and Demographics]]== |
| Treatment of CAP in children depends on both the age of the child and the severity of his/her illness. Children less than five do not typically receive treatment to cover atypical bacteria. If a child does not need to be hospitalized, [[amoxicillin]] for seven days is a common treatment. However, with increasing prevalence of DRSP, other agents such as cefpodoxime will most likely become more popular in the future.{{ref|Bradley}} Hospitalized children should receive intravenous [[ampicillin]], [[ceftriaxone]], or [[cefotaxime]].
| |
|
| |
|
| ===Adults=== | | ==[[Community-acquired pneumonia risk factors|Risk Factors]]== |
|
| |
|
| In [[2001]], the American Thoracic Society, drawing on work by the British and Canadian Thoracic Societies, established guidelines for the management of adults with CAP which divided individuals with CAP into four categories based upon common organisms encountered.{{ref|Neiderman}}
| | ==[[Community-acquired pneumonia screening|Screening]]== |
|
| |
|
| *''Healthy outpatients without risk factors''
| | ==[[Community-acquired pneumonia natural history, complications and prognosis|Natural History, Complications and Prognosis]]== |
| :This group, the largest, is composed of otherwise healthy patients without risk factors for DRSP, enteric Gram negative bacteria, ''Pseudomonas'', or other less common causes of CAP. The primary microoganisms in this group are viruses, atypical bacteria, penicillin sensitive ''Streptococcus pneumoniae'', and ''Hemophilus influenzae''. Recommended management is with a macrolide antibiotic such as [[azithromycin]] or [[clarithromycin]] for seven<ref name="pmid17765048">
| |
| Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007 Sep;120(9):783-90. PMID 17765048</ref> to ten days.
| |
|
| |
|
| *''Outpatients with underlying illness and/or risk factors''
| | ==Diagnosis== |
| :This group does not require hospitalization; its members either have underlying health problems (such as [[emphysema]] or [[congestive heart failure]]) or is at risk for DRSP and/or enteric Gram negative bacteria. Treatment is with a [[fluoroquinolone]] active against ''Streptococcus pneumoniae'' such as [[levofloxacin]] or a [[beta-lactam antibiotic]] such as [[cefpodoxime]], [[cefuroxime]], [[amoxicillin]], or [[Co-amoxiclav|amoxicillin/clavulanate]] plus a macrolide antibiotic such as [[azithromycin]] or [[clarithromycin]] for seven to ten days.
| |
|
| |
|
| *''Hospitalized individuals not at risk for Pseudomonas''
| | [[Community-acquired pneumonia severity criteria| Severity Criteria]] | [[Community-acquired pneumonia history and symptoms| History and Symptoms]] | [[Community-acquired pneumonia physical examination | Physical Examination]] | [[Community-acquired pneumonia laboratory findings |Laboratory Findings]] | [[Community-acquired pneumonia chest x ray|Chest X Ray]] | [[Community-acquired pneumonia CT|CT]] | [[Community-acquired pneumonia ultrasound|Ultrasound]] | [[Community-acquired pneumonia other diagnostic studies|Other Diagnostic Studies]] |
| :This group requires hospitalization and administration of intravenous antibiotics. Treatment is with either an intravenous [[fluoroquinolone]] active against ''Streptococcus pneumoniae'' such as [[levofloxacin]] or [[beta-lactam antibiotic]] such as cefotaxime, ceftriaxone, ampicillin/sulbactam, or high-dose ampicillin plus an intravenous macrolide antibiotic such as [[azithromycin]] or [[clarithromycin]] for seven to ten days.
| |
|
| |
|
| *''Individuals requiring intensive care at risk for Pseudomonas''
| | ==Treatment== |
| :Individuals being treated in an intensive care unit with risk factors for infection with ''Pseudomonas aeruginosa'' require specific antibiotics targeting this difficult to eradicate bacteria. One possible regimen is an intravenous antipseudomonal beta-lactam such as [[cefepime]], [[imipenem]], [[meropenem]], or [[piperacillin|piperacillin/tazobactam]] plus an intravenous antipseudomonal fluoroquinolone such as [[levofloxacin]]. Another recommended regimen is an intravenous antipseudomonal beta-lactam such as cefepime, imipenem, meropenem, or piperacillin/ tazobactam plus an intravenous aminoglycoside such as [[gentamicin]] or [[tobramycin]] plus either an intravenous macrolide such azithromycin or an intravenous nonpseudomonal fluoroquinolone such as [[ciprofloxacin]].
| |
|
| |
|
| == Prevention ==
| | [[Community-acquired pneumonia medical therapy|Medical Therapy]] | [[Community-acquired pneumonia primary prevention|Primary Prevention]] | [[Community-acquired pneumonia cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Community-acquired pneumonia future or investigational therapies|Future or Investigational Therapies]] |
| * Smoking cessation is important not only for treatment of any underlying lung disease, but also because cigarette smoke interferes with many of the body's natural defenses against CAP.
| |
| * Vaccinations against ''[[Haemophilus influenzae]]'' and ''[[Streptococcus pneumoniae]]'' in the first year of life have greatly reduced their role in CAP in children.
| |
| * A vaccine against ''[[Streptococcus pneumoniae]]'' and [[influenza]] are also available for adults and is currently recommended for all healthy individuals older than 65 and any adults with [[emphysema]], [[congestive heart failure]], [[diabetes mellitus]], [[cirrhosis]], [[alcoholism]], [[cerebrospinal fluid]] leaks, or who do not have a [[asplenia|spleen]].
| |
| * A repeat vaccination may also be required after five or ten years.{{ref|Butler}}
| |
| * In addition, health care workers, nursing home residents, and pregnant women should receive the vaccine.{{ref|CDC}}
| |
| * When an influenza outbreak is occurring, medications such as [[amantadine]], [[rimantadine]], [[zanamivir]], and [[oseltamivir]] have been shown to prevent cases of influenza.{{ref|Hayden}}
| |
|
| |
|
| ==References== | | ==Case Studies== |
| {{Reflist}}
| |
| #{{note|Sharma}} [http://www.emedicine.com/med/topic1852.htm Emedicine review of bacterial pneumonia]
| |
| #{{note|Metaly}} Metaly JP, Schulz R, Li Y-H, Singer DE, Marrie TJ, Coley CM, Hough LJ, Obrosky DS, Kapoor WN, Fine MJ. ''Influence of age on symptoms at presentation in patients with community-acquired pneumonia.'' Arch Intern Med 1997; 157: 1453-1459 PMID 9224224
| |
| #{{note|Metlay}} Metlay, JP, Kapoor, WN, Fine, MJ. D''oes this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination.'' JAMA 1997; 278:1440. PMID 9356004
| |
| #{{note|Syrjala}} Syrjala H, Broas M, Suramo I, Ojala A, Lahde S. ''High resolution computed tomography for the diagnosis of community-acquired pneumonia.'' Clin Infect Dis 1998; 27: 358-363 PMID 9709887
| |
| #{{note|Webber}} Webber, S, Wilkinson, AR, Lindsell, D, et al. ''Neonatal pneumonia.'' Arch Dis Child 1990; 65:207.PMID 2107797
| |
| #{{note|Abzug}} Abzug, MJ, Beam, AC, Gyorkos, EA, Levin, MJ. ''Viral pneumonia in the first month of life.'' Pediatr Infect Dis J 1990; 9:881. PMID 2177540
| |
| #{{note|Wubbel}} Wubbel, L, Muniz, L, Ahmed, A, et al. ''Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J 1999; 18:98.'' PMID 10048679
| |
| #{{note|Roux}} de Roux, A, Marcos, MA, Garcia, E, et al. ''Viral community-acquired pneumonia in nonimmunocompromised adults.'' Chest 2004; 125:1343.PMID 15078744
| |
| #{{note|Ruhe}} Ruhe, JJ, Myers, L, Mushatt, D, Hasbun, R. ''High-level penicillin-nonsusceptible Streptococcus pneumoniae bacteremia: identification of a low-risk subgroup.'' Clin Infect Dis 2004; 38:508 PMID 14765343
| |
| #{{note|Lieberman}} Lieberman D, Schlaeffer F, Boldur I, Lieberman D, Horowitz S, Friedman MG, Leiononen M, Horovitz O, Manor E, Porath A. ''Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients.'' Thorax 1996; 51: 179-184 PMID 8711652
| |
| #{{note|Bradley}} Bradley, JS. ''Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines.'' Pediatr Infect Dis J 2002; 21:592. PMID 12182396
| |
| #{{note|Neiderman}} Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, et al. ''Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention.'' Am J Respir Crit Care Med 2001;163:1730–1754 PMID 11401897
| |
| #{{note|Mundy}} Mundy, LM, Auwaerter, PG, Oldach, D, et al. ''Community-acquired pneumonia: impact of immune status.'' Am J Respir Crit Care Med 1995; 152:1309. PMID 7551387
| |
| #{{note|Fine}} Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. ''A prediction rule to identify low-risk patients with community-acquired pneumonia.'' N Engl J Med 1997; 336: 243-250 PMID 8995086
| |
| #{{note|Woodhead}} Woodhead MA, MacFarlane JT, McCracken JS, Rose DH, Finch RG. ''Prospective study of the aetiology and outcome of pneumonia in the community.'' Lancet 1987; i: 671-674. PMID 2882091
| |
| #{{note|Garenne}} Garenne, M, Ronsmans, C, Campbell, H. ''The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries.'' World Health Stat Q 1992; 45:180. PMID 1462653
| |
| #{{note|Almirall}} Almirall, J, Bolibar, I, Balanzo, X, Gonzalez, CA. ''Risk factors for community-acquired pneumonia in adults: A population-based case-control study.'' Eur Respir J 1999; 13:349. PMID 10065680
| |
| #{{note|Butler}} Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. ''Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations.'' JAMA 1993; 270: 1826-1831. PMID 8411526
| |
| #{{note|CDC}} Centers for Disease Control and Prevention. ''Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP)''. MMWR 1999;48(RR-4):1-28.
| |
| #{{note|Hayden}} Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG. ''Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.'' N Engl J Med 1999; 341: 1336-1343 PMID 10536125
| |
| ==References==
| |
| {{reflist|2}}
| |
|
| |
|
| [[Category:Diseaase]] | | [[Community-acquired pneumonia case study one|Case #1]] |
| | |
| | [[Category:Disease]] |
| [[Category:Pulmonology]] | | [[Category:Pulmonology]] |
| [[Category:Infectious disease]]
| |
| [[Category:Pneumonia|Pneumonia]] | | [[Category:Pneumonia|Pneumonia]] |
| [[Category:Emergency medicine]] | | [[Category:Emergency medicine]] |
|
| |
| {{WH}}
| |
| {{WS}}
| |
